S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
2 Long-Term EV Plays Trading Under $20
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
2 Long-Term EV Plays Trading Under $20
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
2 Long-Term EV Plays Trading Under $20
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
Walmart Leads Retail Higher But Will The Group Follow? 
What's in big Biden bill? Health, climate goals become law
Could Biden's Executive Order 14017 Trigger A BULL RUN For This Little-Known Industry? (Ad)
Biden to sign massive climate and health care legislation
Stocks edge mostly higher on Wall Street; Walmart lifts Dow
2 Long-Term EV Plays Trading Under $20
Forget Tesla, THIS Could be the Biggest EV Investment Play in 2022 (Ad)
NASDAQ:CNCE

Concert Pharmaceuticals - CNCE Stock Forecast, Price & News

$6.72
-0.20 (-2.89%)
(As of 08/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.36
$6.99
50-Day Range
$4.09
$7.20
52-Week Range
$2.57
$7.37
Volume
585,838 shs
Average Volume
643,505 shs
Market Capitalization
$244.14 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Concert Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
78.6% Upside
$12.00 Price Target
Short Interest
Healthy
3.03% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.93
Upright™ Environmental Score
News Sentiment
1.37mentions of Concert Pharmaceuticals in the last 14 days
Based on 5 Articles This Week
Insider Trading
Acquiring Shares
$49,998 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.72) to ($1.75) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.67 out of 5 stars

Medical Sector

109th out of 1,124 stocks

Pharmaceutical Preparations Industry

42nd out of 555 stocks

CNCE stock logo

About Concert Pharmaceuticals (NASDAQ:CNCE) Stock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Concert Pharmaceuticals Stock Performance

Shares of NASDAQ:CNCE traded down $0.20 during midday trading on Tuesday, hitting $6.72. 585,838 shares of the company's stock traded hands, compared to its average volume of 454,784. The firm has a fifty day moving average of $5.10 and a 200 day moving average of $4.08. Concert Pharmaceuticals has a 1 year low of $2.57 and a 1 year high of $7.37. The stock has a market capitalization of $244.13 million, a price-to-earnings ratio of -1.97 and a beta of 0.69.

Analyst Ratings Changes

Separately, StockNews.com began coverage on shares of Concert Pharmaceuticals in a research note on Wednesday, June 15th. They set a "hold" rating for the company.

Insider Activity at Concert Pharmaceuticals

In other Concert Pharmaceuticals news, Director Heek Christi Van purchased 10,526 shares of the firm's stock in a transaction on Monday, June 6th. The shares were acquired at an average cost of $4.75 per share, for a total transaction of $49,998.50. Following the completion of the transaction, the director now owns 25,651 shares of the company's stock, valued at $121,842.25. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.80% of the stock is currently owned by company insiders.

Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Stock News Headlines

Recap: Concert Pharma Q2 Earnings
Concert Pharmaceuticals: A Balanced Risk/Reward
See More Headlines
Receive CNCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Concert Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNCE Company Calendar

Last Earnings
11/09/2021
Today
8/17/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNCE
Employees
64
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$17.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+78.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-80,050,000.00
Net Margins
-245.72%
Pretax Margin
-21,504.86%

Debt

Sales & Book Value

Annual Sales
$32.58 million
Book Value
$3.52 per share

Miscellaneous

Free Float
32,405,000
Market Cap
$244.14 million
Optionable
Optionable
Beta
0.69














CNCE Stock - Frequently Asked Questions

Should I buy or sell Concert Pharmaceuticals stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CNCE shares.
View CNCE analyst ratings
or view top-rated stocks.

What is Concert Pharmaceuticals' stock price forecast for 2022?

3 brokerages have issued 1-year price targets for Concert Pharmaceuticals' shares. Their CNCE share price forecasts range from $9.00 to $17.00. On average, they predict the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 78.6% from the stock's current price.
View analysts price targets for CNCE
or view top-rated stocks among Wall Street analysts.

How have CNCE shares performed in 2022?

Concert Pharmaceuticals' stock was trading at $3.15 at the beginning of 2022. Since then, CNCE stock has increased by 113.3% and is now trading at $6.72.
View the best growth stocks for 2022 here
.

When is Concert Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CNCE earnings forecast
.

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) issued its quarterly earnings results on Tuesday, November, 9th. The biotechnology company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.81) by $0.03. The biotechnology company had revenue of $0.54 million for the quarter, compared to analyst estimates of $0.25 million. Concert Pharmaceuticals had a negative trailing twelve-month return on equity of 116.27% and a negative net margin of 245.72%. During the same period last year, the company posted ($0.60) earnings per share.

What is Roger Tung's approval rating as Concert Pharmaceuticals' CEO?

1 employees have rated Concert Pharmaceuticals Chief Executive Officer Roger Tung on Glassdoor.com. Roger Tung has an approval rating of 100% among the company's employees. This puts Roger Tung in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Concert Pharmaceuticals own?
What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (4.57%), Millennium Management LLC (3.42%), Renaissance Technologies LLC (2.55%), Assenagon Asset Management S.A. (1.51%), AWM Investment Company Inc. (1.39%) and Connor Clark & Lunn Investment Management Ltd. (0.83%). Insiders that own company stock include Heek Christi Van, James V Cassella, Jeffrey A Munsie, Marc A Becker, Nancy Stuart, Roger D Tung and Thomas G Auchincloss.
View institutional ownership trends
.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $6.72.

How much money does Concert Pharmaceuticals make?

Concert Pharmaceuticals (NASDAQ:CNCE) has a market capitalization of $244.14 million and generates $32.58 million in revenue each year. The biotechnology company earns $-80,050,000.00 in net income (profit) each year or ($3.41) on an earnings per share basis.

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The official website for the company is www.concertpharma.com. The biotechnology company can be reached via phone at (781) 860-0045, via email at ir@concertpharma.com, or via fax at 302-636-5454.

This page (NASDAQ:CNCE) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.